The European Medicines Agency (EMA) this Friday advised against using the AstraZeneca vaccine in people with a history of rare bleeding as a way to prevent an adverse reaction to the drug.
This is the EMA’s second preventive vaccine recommendation. Last month, the regulator recommended not giving a second dose to people with blood clotting problems.
According to a Reuters report, the recommendation follows an investigation that analyzes cases of heart inflammation following vaccination with all vaccines.
The EMA Safety Committee noted in its assessment that capillary leak syndrome, also known as Clarkson’s disease, should be added to the AstraZeneca package insert as a new side effect. This is a condition in which blood seeps from the smallest vessels into the muscles and body cavities and is characterized by edema and a drop in blood pressure.
Reuters reports that the EMA began analyzing these cases in April, which is also investigating cases of myocarditis and pericarditis following vaccinations with vaccines from AstraZeneca, Pfizer, Moderna and Johnson & Johnson.
